礼来公司的Omvoh药物在溃疡性结肠炎患者中维持了长达四年的缓解，具有很强的疗效和安全性。 Eli Lilly's Omvoh drug maintained remission in ulcerative colitis patients for up to four years, with strong efficacy and safety.

在LUCENT-3试验中,Elilily的肺炎结肠结膜炎药物Omvoh(mirikizumab-mrkz)显示病人持续恢复了长达四年,这是第一个显示这种长期结果的IL-23p19抑制剂。 Eli Lilly's ulcerative colitis drug Omvoh (mirikizumab-mrkz) showed sustained remission in patients for up to four years in the LUCENT-3 trial, the first IL-23p19 inhibitor to demonstrate such long-term outcomes. 在一年后恢复治疗的患者中,78%的患者仍然在无皮质类固醇的临床恢复治疗中,81%的患者有内皮类恢复治疗,90%的患者报告生活质量有所提高,93%的患者的肠道急症降低。 Among those in remission after one year, 78% remained in corticosteroid-free clinical remission, 81% had endoscopic remission, 90% reported improved quality of life, and 93% saw reduced bowel urgency. 近三分之二的患者表现出了对炎症的深刻愈合。 Nearly two-thirds showed deep healing of inflammation. 该药物在以往生物学失败的病人中仍然有效,四年来没有新的安全顾虑,严重不良事件的发生率为12%。 The drug remained effective in patients who failed prior biologics, with no new safety concerns over four years and a 12% rate of serious adverse events.